IP Verse

Pfizer competitive analysis

Loading summary...

Latest oppositions filed by Pfizer

Explore patent oppositions filed by Pfizer against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 23, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3595727
Lipid Nanoparticle FormulationMODERNAAug 26, 2025
EP4108671
Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses ThereofMODERNAAug 20, 2025
EP3981437
Nucleic Acid VaccinesMODERNAJul 4, 2025
EP4023249
Nucleic Acid VaccinesMODERNAJul 4, 2025
EP4032979
Factor Ix Polypeptide Mutant, Its Uses And A Method For Its ProductionUNIQURE BIOPHARMAJan 31, 2025
EP3638696
Use Of Anti Cd70 Antibody Argx-110 To Treat Acute Myeloid LeukaemiaARGENXDec 6, 2024
EP3596123
Fc-Optimized Anti-Cd25 For Tumour Specific Cell DepletionCANCER RESEARCH TECHNOLOGYOct 4, 2024
EP3513802
Vector For Liver-Directed Gene Therapy Of Hemophilia And Methods And Use ThereofVRIJE UNIVERSITEIT BRUSSELAug 27, 2024
EP3227333
Bispecific Antibodies Against Cd3Epsilon And Bcma For Use In Treatment Of DiseasesBRISTOL MYERS SQUIBBMay 16, 2024
EP3007724
Compositions And Methods Of Immunizing Against C. DifficileSANOFI PASTEURApr 5, 2024

Latest patents of Pfizer opposed by its competitors

Explore Pfizer's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3781132
Mar 20, 2024Apixaban Formulations1
EP3977993
Jan 31, 2024Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole For Use As A Medicament2
EP3583947
Oct 11, 2023Streptococcus Pneumoniae Capsular Polysaccharides And Conjugates Thereof2
EP2134702
Aug 30, 2023Crystalline Forms Of 6-[2-(Methylcarbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2-Yl)Ethenyl]Indazole Suitable For The Treatment Of Abnormal Cell Growth In Mammals1
EP3269717
Aug 9, 2023Polymorphic And Pseudopolymorphic Forms Of Pharmaceutical Compound Nxl1041
EP3555064
Mar 1, 2023Glp-1 Receptor Agonists And Uses Thereof1
EP3191461
Nov 3, 2021Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole5
EP2357250
Oct 6, 2021Production Of Polypeptides2
EP3498734
Sep 1, 2021Combination Of A Pd-1 Antagonist And A Vegfr Inhibitor For Treating Cancer7
EP3431475
Apr 7, 2021Solid Forms Of A Selective Cdk4/6 Inhibitor4

Latest publications and patents of Pfizer New

Explore the latest publications and patents granted to Pfizer, showcasing their recent innovations and technological advancements.

Last updated on: Oct 18, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Pfizer

EP4578460
Aug 27, 2025Combinations Comprising Benzodioxol As Glp-1R Agonists For Use In The Treatment Of Nash/Nafld And Related DiseasesPending
EP4593876
Aug 6, 2025Immunogenic Compositions Comprising An Rsv F Protein TrimerPending
EP4593828
Aug 6, 2025Combination Of Talazoparib And Enzalutamide In The Treatment Of Metastatic Castration-Resistant Prostate CancerPending
EP4299135
Aug 6, 2025Benzisoxazole Sulfonamide DerivativesGranted
EP4590708
Jul 30, 2025B-Cell Maturation Antigen (Bcma) Anti-Idiotypic AntibodiesPending
EP4444708
Jul 30, 2025Melanocortin 4 Receptor Antagonists And Uses ThereofGranted
EP3515942
Jul 30, 2025Diagnostic Anti-Pd-L1 Antibody And Use ThereofGranted
EP4587166
Jul 23, 2025Coaxial Flow Device For Nanoparticle Preparation And Manufacturing Equipment Including Such DevicePending
EP3972596
Jul 16, 2025Combinations Comprising Benzodioxol As Glp-1R Agonists For Use In The Treatment Of Nash/Nafld And Related DiseasesGranted
EP4580631
Jul 9, 2025Dosage Regimens Of Estrogen Receptor DegradersPending

Latest PTAB cases involving Pfizer

Discover the latest PTAB cases involving Pfizer, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 24, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Pfizer

IPR2023-01358Aug 28, 2023PFIZERMODERNAFinal Written Decision - Appealed
IPR2021-01132Jun 17, 2021APOTEXPFIZERTerminated-Settled
IPR2021-00925May 11, 2021PFIZERUNIQURE BIOPHARMAFinal Written Decision
IPR2021-00926May 11, 2021PFIZERUNIQURE BIOPHARMAFinal Written Decision
IPR2021-00928May 11, 2021PFIZERUNIQURE BIOPHARMAFinal Written Decision
IPR2021-00528Feb 10, 2021PFIZERAMGENTerminated-Settled
IPR2020-01252Jul 22, 2020PFIZERNOVO NORDISKTerminated-Settled
IPR2020-00388Jan 4, 2020PFIZERUNIQURE BIOPHARMAFinal Written Decision
IPR2020-00324Dec 19, 2019PFIZERNOVO NORDISKTerminated-Settled
IPR2019-00977May 2, 2019PFIZERSANOFI AVENTIS DEUTSCHLANDTerminated-Other

Peer Comparison New

IP litigation analysis comparing Pfizer with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
PFIZER51874312
GENENTECH - 87 - 65
GLAXOSMITHKLINE29112812
MODERNA57542